​

Estrella Immunopharma Stock (NASDAQ:ESLA)

OwnershipFinancialsChart
Estrella Immunopharma by TradingView

Previous Close

$1.15

52W Range

$0.78 - $3.15

50D Avg

$1.38

200D Avg

$1.44

Market Cap

$45.62M

Avg Vol (3M)

$86.28K

Beta

0.85

Div Yield

-

ESLA Company Profile

Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

3

IPO Date

Sep 14, 2021

Website

ESLA Performance

ESLA Financial Summary

Dec 25Dec 24Jun 24
Revenue---
Operating Income$-13.06M$-8.85M$-7.31M
Net Income$-13.06M$-8.85M$-7.31M
EBITDA$-13.06M$-8.85M$-7.31M
Basic EPS$-0.35$-0.25$-0.21
Diluted EPS$-0.35$-0.25$-0.21

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
EXOZeXoZymes, Inc.
SRZNSurrozen, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
GLSIGreenwich LifeSciences, Inc.
TVGNTevogen Bio Holdings Inc.
TLSATiziana Life Sciences Ltd
ONCYOncolytics Biotech Inc.
TILInstil Bio, Inc.
IMMXImmix Biopharma, Inc.
ATOSAtossa Therapeutics, Inc.